Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919002 | 0.80 | ALDH1A1 (0.32) | ALDH1A1RAPGEF4EGFR | |
| SCHEMBL1588979 | 0.78 | ALDH1A1 (0.55) | ALDH1A1LMNA | |
| SCHEMBL429152 | 0.77 | ALDH1A1 (0.44) | ALDH1A1RAPGEF4CES2CES1EGFR | |
| SCHEMBL241795 | 0.76 | RAB9A (0.46) | ALDH1A1RAPGEF4CES2CES1LMNA | |
| SCHEMBL21844916 | 0.75 | RAPGEF4 (0.38) | RAPGEF4CES2CES1EGFR | |
| SCHEMBL27691414 | 0.73 | ALDH1A1 (0.41) | ALDH1A1LMNA | |
| SCHEMBL2324287 | 0.72 | KMT2A (0.46) | ALDH1A1LMNA | |
| SCHEMBL6783917 | 0.72 | RAPGEF4 (0.46) | ALDH1A1RAPGEF4 | |
| SCHEMBL18844096 | 0.72 | ALDH1A1 (0.40) | ALDH1A1LMNAMPO | |
| SCHEMBL13704093 | 0.72 | KDM5A (0.41) | ALDH1A1EGFRLMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022087422-A9 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022087422-A1 | PYRROLIDINE-3-CARBOXAMIDE DERIVATIVES AND RELATED USES | CHULALONGKORN UNIVERSITY (TH) | 2022-04-28 | — | — | WO | disclosed |
| US-8735425-B2 | Tetrahydroisoquinoline derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-27 | — | — | US | disclosed |
| EP-2256105-B1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2256105-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-12-01 | — | — | EP | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | ALDH1A1 355/4885RAPGEF4 4025/4885CES2 3025/4885 |
| US-20110034481-A1 | NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE | DGAT1, DGAT2, DLAT | ALDH1A1 789/4885RAPGEF4 1371/4885CES2 345/4885 |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | ALDH1A1 412/4885RAPGEF4 4155/4885CES2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.